Dow Up0.15% Nasdaq Up0.21%




News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


  • Income Statement
  • Balance Sheet
  • Cash Flow

Addex Therapeutics Ltd. (ADDXF)

-Other OTC
3.17 0.00(0.00%) Sep 16
ProfileGet Profile for:
Addex Therapeutics Ltd.
12, chemin des Aulx
Geneva, 1228
Switzerland - Map
Phone: 41 22 884 15 55
Fax: 41 22 884 15 56

Index Membership:N/A
Full Time Employees:5

Business Summary 

Addex Therapeutics Ltd., together with its subsidiaries, is engaged in the discovery, development, and commercialization of small-molecule pharmaceutical products for the treatment of human health. The company’s lead products include dipraglurant ADX48621, a metabotropic glutamate receptor (mGluR) 5 negative allosteric modulator that is in Phase IIa clinical trial for the treatment of Parkinson’s disease levodopa-induced dyskinesia; and ADX71149, an mGluR2 positive allosteric modulator (PAM), which is under Phase IIa clinical trial to treat schizophrenia and anxiety. It also develops various preclinical programs comprising GABA-BR PAM for overactive bladder and other disorders; mGluR4 PAM for the treatment of Parkinson’s, multiple sclerosis, and other diseases; GLP1R PAM for type 2 diabetes; and mGluR2 NAM for treating Alzheimer's disease and depression. In addition, the company has discovery programs to identify allosteric modulators, including TrkB PAM for neurodegenerative diseases; and TNFR1 NAM for inflammatory diseases. The company’s product under development also includes ADX71441 for the treatment of alcohol addiction, Charcot-Marie-Tooth disease, and other indications. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGlu2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd. and changed its name to Addex Therapeutics Ltd. in March 2012. Addex Therapeutics Ltd. was founded in 2002 and is headquartered in Geneva, Switzerland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Addex Therapeutics Ltd.

Key Executives 
Mr. Timothy Dyer , 46
Chief Exec. Officer
Dr. Sonia Maria Poli Ph.D., 49
Chief Scientific Officer
Dr. Bruno Bournique ,
Head of Absorption, Distribution, Metabolism and Excretion (ADME) / Pharmacokinetics (PK)
Dr. Werner Henrichi Ph.D., 71
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.